{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:38:43Z","timestamp":1791394723431,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960247"],"award-info":[{"award-number":["81960247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81760447"],"award-info":[{"award-number":["81760447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["S2019QNJJB1056"],"award-info":[{"award-number":["S2019QNJJB1056"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of neuromuscular transmission. The objective was to examine the efficacy and safety of 3,4-diaminopyridine (3,4-DAP) in patients with LEMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched several databases to identify relevant studies, including PubMed, EMBASE, Web of Science, MEDLINE, Cochrane Neuromuscular Disease Group Specialized Register and the Cochrane Central Register of Controlled Trials(CENTRAL). The primary outcome, quantitative myasthenia gravis (QMG) score and the secondary outcome, compound muscle action potentials (CMAP) amplitude were pooled by meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six randomised controlled trials (RCTs) involving 115 patients with LEMS were included. QMG score showed a significant decrease (improvement) of 2.76 points (95\u2009% CI, -4.08 to -1.45,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) after treatment with 3, 4-DAP. Moreover, the overall mean CMAP amplitude improved significantly in LEMS patients with 3, 4-DAP treatment, compared with placebo treatment (mean difference 1.34 mV, 95\u2009% CI, 0.98 to 1.70,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The overall assessment of all included trials showed a low risk of bias and low heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The pooled results of RCTs demonsrated with moderate to high evidence that 3,4-DAP has a significant effect on LEMS treatment, with improvements in muscle strength score and CMAP amplitude.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-021-02405-3","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T03:02:36Z","timestamp":1632538956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"21","author":[{"given":"Na","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-8950","authenticated-orcid":false,"given":"Taohui","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"3","key":"2405_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.12998\/wjcc.v3.i3.293","volume":"3","author":"CE Bekircan-Kurt","year":"2015","unstructured":"Bekircan-Kurt CE, Derle Ciftci E, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases. 2015;3(3):293\u2013300.","journal-title":"World J Clin Cases"},{"issue":"2","key":"2405_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03020488","volume":"49","author":"M Yamakage","year":"2002","unstructured":"Yamakage M, Namiki A. Calcium channels\u2013basic aspects of their structure, function and gene encoding; anesthetic action on the channels\u2013a review. Can J Anaesth. 2002;49(2):151\u201364.","journal-title":"Can J Anaesth"},{"issue":"2","key":"2405_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","volume":"4","author":"R Mantegazza","year":"2015","unstructured":"Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS registry: baseline demographics and treatment approaches. Neurol Ther. 2015;4(2):105\u201324.","journal-title":"Neurol Ther"},{"key":"2405_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1196\/annals.1254.065","volume":"998","author":"DB Sanders","year":"2003","unstructured":"Sanders DB. Lambert-eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003;998:500\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2405_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/088307380201700123","volume":"17","author":"CY Tsao","year":"2002","unstructured":"Tsao CY, Mendell JR, Friemer ML, Kissel JT. Lambert-Eaton myasthenic syndrome in children. J Child Neurol. 2002;17(1):74\u20136.","journal-title":"J Child Neurol"},{"issue":"9","key":"2405_CR6","doi-asserted-by":"publisher","first-page":"Np58","DOI":"10.1177\/0883073813499970","volume":"29","author":"S Portaro","year":"2014","unstructured":"Portaro S, Parisi D, Polizzi A, Ruggieri M, Andreetta F, Bernasconi P, Toscano A, Rodolico C. Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome. J Child Neurol. 2014;29(9):Np58-61.","journal-title":"J Child Neurol"},{"issue":"4","key":"2405_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","volume":"104","author":"PW Wirtz","year":"2002","unstructured":"Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359\u201363.","journal-title":"Clin Neurol Neurosurg"},{"key":"2405_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1196\/annals.1405.030","volume":"1132","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129\u201334.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2405_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3111\/13696998.2012.660897","volume":"15","author":"L Harms","year":"2012","unstructured":"Harms L, Sieb JP, Williams AE, Graham R, Shlaen R, Claus V, Pfiffner C. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521\u201330.","journal-title":"J Med Econ"},{"issue":"2","key":"2405_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","volume":"160","author":"J Newsom-Davis","year":"2004","unstructured":"Newsom-Davis J. Lambert-Eaton myasthenic syndrome. Rev Neurol. 2004;160(2):177\u201380.","journal-title":"Rev Neurol"},{"issue":"12","key":"2405_CR11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098\u2013107.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2405_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35\u201342.","journal-title":"J Neurol Sci"},{"issue":"13","key":"2405_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jama.1957.02970480021005","volume":"163","author":"LM Eaton","year":"1957","unstructured":"Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957;163(13):1117\u201324.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"2405_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2405_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ncl.2018.01.008","volume":"36","author":"VG Kesner","year":"2018","unstructured":"Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton Myasthenic Syndrome. Neurol Clin. 2018;36(2):379\u201394.","journal-title":"Neurol Clin"},{"issue":"1","key":"2405_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jpba.2006.06.007","volume":"43","author":"JA Raust","year":"2007","unstructured":"Raust JA, Goulay-Dufay S, Le Hoang MD, Pradeau D, Guyon F, Do B. Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products. J Pharm Biomed Anal. 2007;43(1):83\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"2405_CR17","first-page":"1290","volume":"28","author":"M van Tulder","year":"2003","unstructured":"van Tulder M, Furlan A, Bombardier C, Bouter L. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine. 2003;28(12):1290\u20139.","journal-title":"Spine"},{"issue":"7414","key":"2405_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"23","key":"2405_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321(23):1567\u201371.","journal-title":"N Engl J Med"},{"issue":"3","key":"2405_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603\u20137.","journal-title":"Neurology"},{"issue":"5","key":"2405_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/mus.21422","volume":"40","author":"SJ Oh","year":"2009","unstructured":"Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40(5):795\u2013800.","journal-title":"Muscle Nerve"},{"issue":"5","key":"2405_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.25070","volume":"53","author":"SJ Oh","year":"2016","unstructured":"Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, et al. Amifampridine phosphate (Firdapse((R))) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717\u201325.","journal-title":"Muscle Nerve"},{"issue":"3","key":"2405_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CND.0000000000000239","volume":"20","author":"P Shieh","year":"2019","unstructured":"Shieh P, Sharma K, Kohrman B, Oh SJ. Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS. J Clin Neuromuscul Dis. 2019;20(3):111\u20139.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"2405_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","volume":"61","author":"J Molgo","year":"1980","unstructured":"Molgo J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol. 1980;61(1):25\u201334.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2405_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"key":"2405_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","journal-title":"Ann N Y Acad Sci"},{"key":"2405_CR27","doi-asserted-by":"crossref","unstructured":"Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;2011(2):CD003279.","DOI":"10.1002\/14651858.CD003279.pub3"},{"key":"2405_CR28","doi-asserted-by":"crossref","unstructured":"Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2005;(2):CD003279.","DOI":"10.1002\/14651858.CD003279.pub2"},{"key":"2405_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1749-6632.2012.06769.x","volume":"1275","author":"P Maddison","year":"2012","unstructured":"Maddison P. Treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 2012;1275:78\u201384.","journal-title":"Ann N Y Acad Sci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02405-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02405-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02405-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T03:03:53Z","timestamp":1632539033000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02405-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2405"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02405-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-34187\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-34187\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"7 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}